Kolexia
Lombard Bohas Catherine Oncologie médicale
Lombard Bohas Catherine
Oncologie médicale
Hôpital Edouard Herriot
Lyon, France
213 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs neuroendocrines Tumeurs du pancréas Métastase tumorale Tumeur carcinoïde Carcinomes Carcinome neuroendocrine Tumeurs du foie Tumeurs du poumon Adénome langerhansien

Collaborateurs

Voir plus
Walter Thomas
Walter Thomas
Hôpital Edouard Herriot, Lyon, France
Baudin Eric
Baudin Eric
Gustave-Roussy, Villejuif, France
Ruszniewski Philippe
Ruszniewski Philippe
Hôpital Beaujon, Clichy, France
Scoazec Jean-Yves
Scoazec Jean-Yves
Gustave-Roussy, Villejuif, France

Industries

Voir plus
Ipsen
29 collaboration(s)
Dernière en 2023
Advanced Accelerator Applications
14 collaboration(s)
Dernière en 2023
ADVANCED ACCELERATOR APPLICATIONS
3 collaboration(s)
Dernière en 2023
Novartis
2 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
PROFILER: Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Essai Clinique (Centre Léon-Bérard)   01 mars 2024
OPALINE: AN OBSERVATIONAL REAL-WORLD STUDY OF THE SYSTEMIC TREATMENT OF WELL-DIFFERENTIATED, UNRESECTABLE OR METASTATIC, PROGRESSIVE PANCREATIC NEUROENDOCRINE TUMOURS (PNET): A STUDY OF MORBIDITY AND MORTALITY AT 2 YEARS
Essai Clinique (Pfizer)   09 novembre 2023
LBA54 Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Surgery of primary lung carcinoid tumors at metastatic stage: A national study from the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network.
Journal of neuroendocrinology   21 août 2023
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
Annals of oncology : official journal of the European Society for Medical Oncology   07 août 2023
ADOPT-PRESTAGE: Randomized Controlled Trial on Acceptability, Diffusion and Impact on Treatment Adherence and Persistence of the PRESTAGE Program (Program for Education and Support for Oral Cancer Treatments in the Elderly) - Randomized Controlled Study Evaluating the Impact of the Program PRESTAGE
Essai Clinique (Hospices Civils de Lyon)   12 mai 2023
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study.
Endocrine-related cancer   26 avril 2023
BEVANEC: Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment After the Failure of the Cisplatin (or Carboplatin)-Etoposide Combination in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer. A Phase 2 Non-comparative Randomized Study
Essai Clinique (Hospices Civils de Lyon)   18 avril 2023
Carcinoid heart disease in patients with midgut neuroendocrine tumours.
Journal of neuroendocrinology   02 avril 2023
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.
The Lancet. Oncology   02 février 2023